$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice

2014-08

2016-04

2016-04

9

Study Overview

Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice

Currently, X-rays and blood tests often miss pancreatic cancer. In this study, we are collecting and studying the fluid produced by the pancreas as a way to detect pancreatic cancer at an earlier stage.

Pancreatic cancer is very difficult to detect and treat, and patients with this cancer generally live fewer years than patients with other types of cancer. Part of the reason why pancreatic cancer is so hard to treat is because it is usually discovered when it is too advanced to be able to treat. The goal of this protocol is to find a way to detect pancreatic cancer earlier, when it is still treatable in order to improve the survival of patients. The pancreas is a gland which produces digestive juices that mix with food in the intestines. Normal patients as well as patients with pancreatic cancer produce these juices. Other researchers have collected this fluid from very small numbers of patients and their results suggest that pancreatic fluid can be used to detect pancreatic cancer. One of the major issues with these results is that pancreatic fluid from only a very few number of patients has been collected and analyzed. In order to find out whether the pancreatic fluid can be used as a standard test for pancreatic cancer, the fluid from a greater number of patients needs to be analyzed. Also, of all the different chemicals in the pancreatic fluid, in this study we will try to figure out what the most important chemicals are in diagnosing pancreatic cancer.

  • Pancreatic Cancer
    • UAB 1361

    Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates Results Reporting Dates Study Record Updates

    2014-10-06  

    N/A  

    2016-05-11  

    2014-10-27  

    N/A  

    2016-05-13  

    2014-10-29  

    N/A  

    2016-05  

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    Design Details

    Primary Purpose:
    N/A

    Allocation:
    N/A

    Interventional Model:
    N/A

    Masking:
    N/A

    Arms and Interventions

    Participant Group/ArmIntervention/Treatment
    : pancreatic adenocarcinoma

    15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).

    : chronic pancreatitis

    15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .

    : non-pancreatic, non-neoplastic disorders

    15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.

    Primary Outcome MeasuresMeasure DescriptionTime Frame
    Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease processCharacterization of the proteomic signature of patients with pancreatic adenocarcinoma, pancreatic cancer, and control participants. This will be accomplished by classifying a group or set of similar proteomic profiles(once we(once we have developed from the samples obtained a list of known proteomic profiles taht are found in all pancreatic adenocarcinoma subjects) that are specific to the disease process,of pancreatic adenocarcinoma.120 months from First subject enrolled
    Secondary Outcome MeasuresMeasure DescriptionTime Frame
    Compare the proteomic profile between pancreatic cancer and pancreatitisUsing the discovered pancreatic adenocarcinoma proteomic profile we will differentiate a documentable difference from pancreatic cancer and pancreatitis120 months from First subject enrolled

    Contacts and Locations

    This section provides the contact details for those conducting the study, and information on where this study is being conducted.

    Participation Criteria

    Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

    Ages Eligible for Study:
    ALL

    Sexes Eligible for Study:
    19 Years

    Accepts Healthy Volunteers:

      Inclusion Criteria:Group A:
      1. Male or females that have suspected pancreatic adenocarcinoma, localized or metastatic. 2. The pancreatic adenocarcinoma must be active, with active intra-pancreatic tumor documented within the last 3 months by CT or MRI scan. 3. At least 19 years of age. (All Cohorts) 4. In the Investigator's judgment, participant is mentally competent to provide informed consent to participate in the study. (All Cohorts) 5. Eastern Cooperative Oncology Group(ECOG) performance status of 0-2. (All Cohorts) 6. Negative urine pregnancy test at screening, if applicable. (All Cohorts) 7. The patient must already have a completed, active consent for either endoscopic ultrasound(EUS) and/or endoscopic retrograde cholangiopancreatography (ERCP) at University of Alabama at Birmingham(UAB). (All Cohorts)
      Group B:
      1. Male or female patients that have had chronic pancreatitis for at least 6 months. 2. CT abdomen or MRI abdomen within the last 3 months demonstrating no suspicion of pancreatic adenocarcinoma.
      Group C:
      1.Male or female patients already scheduled to undergo upper endoscopy for non-pancreatic, non-neoplastic indications.
      Exclusion Criteria:Group A:
      1. The participant is medically unfit to undergo upper endoscopy. 2. No cancer-directed therapy administered within the last 3 months. This includes any of the following: surgical resection, chemotherapy, radiation therapy, immunologic or biologic therapy. 3. Participants with a known allergy to secretin. 4. Participants who are pregnant or lactating, or intending to become pregnant during the study. 5. Participants of childbearing potential who refuse a pregnancy test. 6. Participants who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures. 7. Participants who have participated in an investigational surgical, drug, or device study within the past 30 days. 8. Participants who currently have a biliary stent in place. 9. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 10. The endoscopic pancreatic biopsy does not show adenocarcinoma.
      Group B:
      1. The participant is medically unfit to undergo upper endoscopy. 2. The participant has a suspicion of pancreatic adenocarcinoma on imaging within the last 3 months. 3. Participants with a known allergy to secretin. 4. Participants who are pregnant or lactating, or intending to become pregnant during the study. 5. Participants of childbearing potential who refuse a pregnancy test. 6. Participants who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures. 7. Participants who have participated in an investigational surgical, drug, or device study within the past 30 days. 8. Participants who currently have a biliary stent in place. 9. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
      Group C:
      1. The participant is medically unfit to undergo upper endoscopy. 2. The participant has a history of, or current clinical suspicion of pancreatic adenocarcinoma or pancreatitis. 3. The participant has a history of any type of gastrointestinal malignancy within the last 5 years. 4. Participants with a known allergy to secretin. 5. Participants who are pregnant or lactating, or intending to become pregnant during the study. 6. Participants of childbearing potential who refuse a pregnancy test. 7. Participants who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures. 8. Participants who have participated in an investigational surgical, drug, or device study within the past 30 days. 9. Participants who currently have a biliary stent in place. 10. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
      -

    Collaborators and Investigators

    This is where you will find people and organizations involved with this study.

      • PRINCIPAL_INVESTIGATOR: Carlo M Contreras, MD, University of Alabama at Birmingham

      Publications

      The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

      General Publications

      No publications available

      Treat yourself

      Let Us Take Care Of You

      BOOK AN APPOINTMENT ⟶
      footer logo

      About

      Events

      Fundraising

      Contact Us

      Facebook-f Instagram

      NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

      The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

      Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

      Make-A-Will Month

      Snag 6508be92
      Learn More
      Donate Now Online
      Other Ways to Donate